Pioglitazone Improves In Vitro Viability and Function of Endothelial Progenitor Cells from Individuals with Impaired Glucose Tolerance

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Spigoni, Valentina ^a   Picconi, Angela ^b   Cito, Monia ^b   Ridolfi, Valentina ^b   Bonomini, Sabrina ^b   Casali, Chiara ^b   Zavaroni, Ivana ^b   Gnudi, Luigi ^c   Metra, Marco ^a   Dei Cas, Alessandra ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; INTERCELLULAR ADHESION MOLECULE 1; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL GROWTH; CELL STRUCTURE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL PROGENITOR CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; MALE; PROTEIN EXPRESSION;

APOPTOSIS; CELL ADHESION MOLECULES; CELL SURVIVAL; CHEMOKINES; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE INTOLERANCE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NF-KAPPA B; STEM CELLS; THIAZOLIDINEDIONES;

EID: 84868350514     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048283     Document Type: Article

References (49)

1. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, et al. (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media JAMA. 296: 2572-81.
2. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, et al. (2005) PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-89.
3. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H, (1980) Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1: 1373-6.
4. Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, et al. (2011) Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging 4: 1110-8.
5. Yang HB, Zhao XY, Zhang JY, Du YY, Wang XF Pioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose tolerance. Diabet Med. (in press).
6. Nakayama T, Komiyama N, Yokoyama M, Namikawa S, Kuroda N, et al. (2010) Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol 138: 157-65.
7. Quinn CE, Lockhart CJ, Hamilton PK, Loughrey CM, McVeigh GE, (2010) Effect of pioglitazone on endothelial function in impaired glucose tolerance. Diabetes Obes Metab 12: 709-15.
8. Duan SZ, Usher MG, Mortensen RM, (2008) Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 102: 283-94.
9. Brown JD, Plutzky J, (2007) Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115: 518-33.
10. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, et al. (1997) Isolation of putative progenitor endothelial cells for angiogenesis Science. 275: 964-7.
11. Kirton JP, Xu Q, (2010) Endothelial precursors in vascular repair. Microvasc Res 79: 193-9.
12. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, et al. (2001) Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89: E1-E7.
13. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593-600.
14. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, et al. (2002) Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106: 2781-2786.
15. Fadini GP, de Kreutzenberg SV, Coracina A, Baesso I, Agostini C, et al. (2006) Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur.Heart J 27: 2247-2255.
16. Dei Cas A, Spigoni V, Ardigò D, Pedrazzi G, Franzini L, et al. (2011) Reduced circulating endothelial progenitor cell number in healthy young adult hyperinsulinemic men. Nutr Metab Cardiovasc Dis 21: 512-7.
17. Fadini GP, Pucci L, Vanacore R, Baesso I, Penno G, et al. (2007) Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia 50: 2156-63.
18. Rohde E, Malischnik C, Thaler D, Maierhofer T, Linkesch W, et al. (2006) Blood monocytes mimic endothelial progenitor cells. Stem Cells 24: 357-367.
19. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, et al. (2004) Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 24: 288-293.
20. Wang CH, Ting MK, Verma S, Kuo LT, Yang NI, et al. (2006) Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J 152: 1051.e1-8.
21. Werner C, Kamani CH, Gensch C, Böhm M, Laufs U, (2007) The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 56: 2609-15.
22. Pasceri V, Wu HD, Willerson JT, Yeh ET, (2000) Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101: 235-8.
23. Akhter J, (1997) The American Diabetes Association's Clinical Practice Recommendations and the developing world. Diabetes Care 20: 1044-1045.
24. Fadini GP, Losordo D, Dimmeler S, (2012) Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 110(4): 624-37.
25. Prater DN, Case J, Ingram DA, Yoder MC, (2007) Working hypothesis to redefine endothelial progenitor cells. Leukemia 21: 1141-9.
26. Majithiya JB, Paramar AN, Balaraman R, (2005) Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res 66: 150-61.
27. Arnaoutova I, George J, Kleinman HK, Benton G, (2009) The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis 12: 267-74.
28. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-8.
29. Renard P, Ernest I, Houbion A, Art M, Le Calvez H, et al. (2001) Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res 29: E21.
30. Rehman J, Li J, Orschell CM, March KL, (2003) Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107: 1164-9.
31. Walcher D, Marx N, (2004) Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action. Diab Vasc Dis Res 1: 76-81.
32. Redondo S, Hristov M, Gümbel D, Tejerina T, Weber C, (2007) Biphasic effect of pioglitazone on isolated human endothelial progenitor cells: involvement of peroxisome proliferator-activated receptor-gamma and transforming growth factor-beta1. Thromb Haemost 97: 979-87.
33. Medina RJ, O'Neill CL, Sweeney M, Guduric-Fuchs J, Gardiner TA, et al. (2010) Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med Genomics 3: 18.
34. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, et al. (2000) Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A. 97: 3422-7.
35. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, et al. (2001) Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103: 634-7.
36. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, et al. (2007) Re-defining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109: 1801-9.
37. Ingram DA, Mead LE, Moore DB, Woodard W, Fenoglio A, et al. (2005) Vessel wall-derived endothelial cells rapidly proliferate because they contain a complete hierarchy of endothelial progenitor cells. Blood 105: 2783-6.
38. Gensch C, Clever YP, Werner C, Hanhoun M, Böhm M, et al. (2007) The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 192: 67-74.
39. Schernthaner G, (2009) Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int J Clin Pract 63: 912-29.
40. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, et al. (2003) Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9: 1370-6.
41. Marx N, Walcher D, (2007) Vascular effects of PPARgamma activators- from bench to bedside. Prog Lipid Res 46: 283-96.
42. Ishibashi M, Egashira K, Hiasa K, Inoue S, Ni W, et al. (2002) Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 40: 687-93.
43. Yuan Z, Liu Y, Liu Y, Zhang J, Kishimoto C, et al. (2005) Cardioprotective effects of peroxisome proliferator activated receptor gamma activators on acute myocarditis: anti-inflammatory actions associated with nuclear factor kappaB blockade. Heart 9: 1203-8.
44. Ao C, Huo Y, Qi L, Xiong Z, Xue L, et al. (2010) Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-kappaB. Cell Biol Int 34: 723-30.
45. Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M, et al. (2007) Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol Cell Biol 27: 803-17.
46. Lombardi A, Cantini G, Mello T, Francalanci M, Gelmini S, et al. (2009) Molecular mechanisms underlying the pro-inflammatory synergistic effect of tumor necrosis factor alpha and interferon gamma in human microvascular endothelium. Eur J Cell Biol 88: 731-42.
47. von Knethen A, Soller M, Tzieply N, Weigert A, Johann AM, et al. (2007) PPARgamma1 attenuates cytosol to membrane translocation of PKCalpha to desensitize monocytes/macrophages. J Cell Biol 176: 681-94.
48. Zhang WY, Schwartz EA, Permana PA, Reaven PD, (2008) Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance. Arterioscler Thromb Vasc Biol 28: 2312-8.
49. Wu ZH, Zhao SP, Chu LX, Ye HJ, (2010) Pioglitazone reduces tumor necrosis factor-alpha serum concentration and mRNA expression of adipose tissue in hypercholesterolemic rabbits. Int J Cardiol 138: 151-6.